Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.
Eligibility criteria
Qualifiers
Male or female, any race
Age ≥ 18 years
Capable of providing written informed consent OR having a legally authorized representative (LAR) to provide informed consent for volunteering to undergo research procedure
Has a clinical, radiographic, or pathological diagnosis of primary or secondary CNS malignancy that has not been treated with radiotherapy
Disqualifiers
Hypersensitivity to [C-11]-CS1P1 or any of its excipients
Contraindications to PET, CT or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate
Prior cranial radiotherapy
Severe claustrophobia that would require general anesthesia
Trial design
Treatments tested in this trial
- [C-11]-CS1P1
- Brain MRI
Treatment groups
104 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov